Neurocrine Biosciences (NBIX) 18.58 $NBIX
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
PR Newswire - Tue Nov 04, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference
PR Newswire - Mon Nov 03, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Nomura Biotechnology Conference in Boston.
NBIX: 18.58 (-0.10)
Neurocrine meets 3Q profit forecasts
Automated Insights - Mon Nov 03, 5:00PM CST
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported a third-quarter loss of $15.9 million.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences Reports Third Quarter 2014 Results
PR Newswire - Mon Nov 03, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2014. For the third quarter of 2014, the Company reported a net loss of $15.9 million, or $0.21 loss per share, compared to a net loss of $11.1 million, or $0.17 loss per share, for the same period in 2013. For the nine months ended September 30, 2014, the Company reported a net loss of $41.1 million, or $0.56 loss per share, as compared to net loss of $35.4 million, or $0.53 loss per share, for the first three quarters of last year.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences awarded US FDA's Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
M2 - Fri Oct 31, 11:58AM CDT
Pharmaceutical company Neurocrine Biosciences (NasdaqGS:NBIX) revealed on Thursday the receipt of the US Food and Drug Administration's (FDA) Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in treating tardive dyskinesia.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
PR Newswire - Thu Oct 30, 6:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. A breakthrough therapy designation is granted for a drug that is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on clinically significant endpoints over available therapies. The breakthrough designation also allows intensive discussions with the FDA which are intended to expedite the development and review process of eligible drugs.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 27, 3:05PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2014 financial results after the Nasdaq market closes on Monday, November 3, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Monday afternoon, November 3, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 18.58 (-0.10)
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.13 (-0.07), BCRX: 10.46 (+0.14), NBIX: 18.58 (-0.10), ONTY: 1.60 (-0.07), DYAX: 12.78 (-0.27)
Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
PR Newswire - Mon Oct 20, 3:05PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a randomized, parallel-group, double-blind, placebo-controlled trial of approximately 240 subjects with moderate to severe tardive dyskinesia and an underlying diagnosis of mood disorder, schizophrenia or schizoaffective disorder. The initial six weeks of treatment consists of an efficacy and safety assessment of 80mg and 40mg once-daily NBI-98854 against placebo. This is followed by an additional 46 weeks of long-term safety assessment where all subjects are randomized in a blinded fashion to either 80mg or 40mg once-daily NBI-98854. Topline efficacy data is expected in the second half of 2015.
NBIX: 18.58 (-0.10)
Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
PR Newswire - Thu Oct 02, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences elects Malcolm Lloyd-Smith as chief regulatory officer
M2 - Thu Oct 02, 6:33AM CDT
Pharmaceutical company Neurocrine Biosciences (NasdaqGS:NBIX) revealed on Thursday the appointment of Malcolm Lloyd-Smith as its chief regulatory officer.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer
PR Newswire - Wed Oct 01, 4:20PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Malcolm Lloyd-Smith has joined the executive management team as Chief Regulatory Officer.
NBIX: 18.58 (-0.10)
3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Thu Sep 25, 8:18AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
ZFGN: 19.18 (-0.13), NBIX: 18.58 (-0.10)
Polycystic Ovarian Syndrome Therapeutics Pipeline Review 2014 - 6 Companies & 9 Drug Profiles
M2 - Tue Sep 23, 9:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sgjg9w/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Euroscreen S.A. - Neurocrine Biosciences, Inc. - Merck KGaA - EffRx Pharmaceuticals S.A. - Crinetics Pharmaceuticals, Inc. Drug Profiles - choriogonadotropin alfa - AZD-4901 - ESN-364 - Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology - metformin hydrochloride - Synthetic Peptide to Target GPR54 for Womens Health, Male Health and Oncology - Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome - Small Molecules to Inhibit KISS-1R For Polycystic Ovarian Syndrome - Small Molecules to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia For more information visit http://www.researchandmarkets.com/research/sgjg9w/polycystic
NBIX: 18.58 (-0.10), AZN: 72.88 (+0.03)
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Sep 03, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.
NBIX: 18.58 (-0.10), MS: 35.66 (+0.35)
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
at The Street - Tue Aug 26, 1:22PM CDT
It's not the hedge fund mogul you expect.
ACRX: 6.04 (+0.41), NBIX: 18.58 (-0.10), SRPT: 16.12 (-0.14), QCOM: 69.26 (-1.32), CELG: 106.45 (-0.69)
Neurocrine Biosciences posts higher net loss of USD13.4m for Q2 2014
M2 - Thu Aug 07, 5:02AM CDT
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) disclosed on Wednesday that its net loss was USD13.4m (USD0.18 loss per share) for the second quarter ended 30 June 2014.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences Reports Second Quarter 2014 Results
PR Newswire - Wed Aug 06, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2014. For the second quarter of 2014, the Company reported a net loss of $13.4 million, or $0.18 loss per share, compared to a net loss of $12.2 million, or $0.18 loss per share, for the same period in 2013. For the six months ended June 30, 2014, the Company reported a net loss of $25.2 million, or $0.35 loss per share, as compared to net loss of $24.3 million, or $0.36 loss per share, for the first half of last year.
NBIX: 18.58 (-0.10)
Global PCOS (Stein-Leventhal Syndrome) Drugs Market 2014-2018
M2 - Wed Aug 06, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gszg6d/global_pcos_drugs) has announced the addition of the "Global PCOS Drugs Market 2014-2018" report to their offering. The analysts forecast the Global PCOS Drugs market will grow at a CAGR of 2.665% over the period 2013-2018. PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS. This report covers the present scenario and the growth prospects of the Global PCOS Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of marketed, off-label, and generic drugs used in the treatment of PCOS. The report, the Global PCOS Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PCOS Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Merck & Co. Inc. - Novartis AG - Sanofi SA - Teva Pharmaceutical Inc. Other Prominent Vendors - AstraZeneca plc - Catalysis SL - Crinetics Pharmaceuticals Inc. - Dexa Medica Group - EffRx Inc. - Neurocrine Biosciences Inc. Market Drivers/Challenges/Trends - Increase in Patient Population. - Lack of Approved Drugs. - Increase in Awareness of PCOS Drugs. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For more information visit http://www.researchandmarkets.com/research/gs...pcos_drugs
NBIX: 18.58 (-0.10), MRK: 59.34 (+0.08), AZN: 72.88 (+0.03), NVS: 91.76 (-0.27)
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
PR Newswire - Tue Nov 04, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference
PR Newswire - Mon Nov 03, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Nomura Biotechnology Conference in Boston.
NBIX: 18.58 (-0.10)
Neurocrine meets 3Q profit forecasts
Automated Insights - Mon Nov 03, 5:00PM CST
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported a third-quarter loss of $15.9 million.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences Reports Third Quarter 2014 Results
PR Newswire - Mon Nov 03, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2014. For the third quarter of 2014, the Company reported a net loss of $15.9 million, or $0.21 loss per share, compared to a net loss of $11.1 million, or $0.17 loss per share, for the same period in 2013. For the nine months ended September 30, 2014, the Company reported a net loss of $41.1 million, or $0.56 loss per share, as compared to net loss of $35.4 million, or $0.53 loss per share, for the first three quarters of last year.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences awarded US FDA's Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
M2 - Fri Oct 31, 11:58AM CDT
Pharmaceutical company Neurocrine Biosciences (NasdaqGS:NBIX) revealed on Thursday the receipt of the US Food and Drug Administration's (FDA) Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in treating tardive dyskinesia.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
PR Newswire - Thu Oct 30, 6:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. A breakthrough therapy designation is granted for a drug that is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on clinically significant endpoints over available therapies. The breakthrough designation also allows intensive discussions with the FDA which are intended to expedite the development and review process of eligible drugs.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 27, 3:05PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2014 financial results after the Nasdaq market closes on Monday, November 3, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Monday afternoon, November 3, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 18.58 (-0.10)
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.13 (-0.07), BCRX: 10.46 (+0.14), NBIX: 18.58 (-0.10), ONTY: 1.60 (-0.07), DYAX: 12.78 (-0.27)
Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
PR Newswire - Mon Oct 20, 3:05PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a randomized, parallel-group, double-blind, placebo-controlled trial of approximately 240 subjects with moderate to severe tardive dyskinesia and an underlying diagnosis of mood disorder, schizophrenia or schizoaffective disorder. The initial six weeks of treatment consists of an efficacy and safety assessment of 80mg and 40mg once-daily NBI-98854 against placebo. This is followed by an additional 46 weeks of long-term safety assessment where all subjects are randomized in a blinded fashion to either 80mg or 40mg once-daily NBI-98854. Topline efficacy data is expected in the second half of 2015.
NBIX: 18.58 (-0.10)
Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
PR Newswire - Thu Oct 02, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences elects Malcolm Lloyd-Smith as chief regulatory officer
M2 - Thu Oct 02, 6:33AM CDT
Pharmaceutical company Neurocrine Biosciences (NasdaqGS:NBIX) revealed on Thursday the appointment of Malcolm Lloyd-Smith as its chief regulatory officer.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer
PR Newswire - Wed Oct 01, 4:20PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Malcolm Lloyd-Smith has joined the executive management team as Chief Regulatory Officer.
NBIX: 18.58 (-0.10)
3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Thu Sep 25, 8:18AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
ZFGN: 19.18 (-0.13), NBIX: 18.58 (-0.10)
Polycystic Ovarian Syndrome Therapeutics Pipeline Review 2014 - 6 Companies & 9 Drug Profiles
M2 - Tue Sep 23, 9:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sgjg9w/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Euroscreen S.A. - Neurocrine Biosciences, Inc. - Merck KGaA - EffRx Pharmaceuticals S.A. - Crinetics Pharmaceuticals, Inc. Drug Profiles - choriogonadotropin alfa - AZD-4901 - ESN-364 - Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology - metformin hydrochloride - Synthetic Peptide to Target GPR54 for Womens Health, Male Health and Oncology - Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome - Small Molecules to Inhibit KISS-1R For Polycystic Ovarian Syndrome - Small Molecules to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia For more information visit http://www.researchandmarkets.com/research/sgjg9w/polycystic
NBIX: 18.58 (-0.10), AZN: 72.88 (+0.03)
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Sep 03, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.
NBIX: 18.58 (-0.10), MS: 35.66 (+0.35)
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
at The Street - Tue Aug 26, 1:22PM CDT
It's not the hedge fund mogul you expect.
ACRX: 6.04 (+0.41), NBIX: 18.58 (-0.10), SRPT: 16.12 (-0.14), QCOM: 69.26 (-1.32), CELG: 106.45 (-0.69)
Neurocrine Biosciences posts higher net loss of USD13.4m for Q2 2014
M2 - Thu Aug 07, 5:02AM CDT
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) disclosed on Wednesday that its net loss was USD13.4m (USD0.18 loss per share) for the second quarter ended 30 June 2014.
NBIX: 18.58 (-0.10)
Neurocrine Biosciences Reports Second Quarter 2014 Results
PR Newswire - Wed Aug 06, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2014. For the second quarter of 2014, the Company reported a net loss of $13.4 million, or $0.18 loss per share, compared to a net loss of $12.2 million, or $0.18 loss per share, for the same period in 2013. For the six months ended June 30, 2014, the Company reported a net loss of $25.2 million, or $0.35 loss per share, as compared to net loss of $24.3 million, or $0.36 loss per share, for the first half of last year.
NBIX: 18.58 (-0.10)
Global PCOS (Stein-Leventhal Syndrome) Drugs Market 2014-2018
M2 - Wed Aug 06, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gszg6d/global_pcos_drugs) has announced the addition of the "Global PCOS Drugs Market 2014-2018" report to their offering. The analysts forecast the Global PCOS Drugs market will grow at a CAGR of 2.665% over the period 2013-2018. PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS. This report covers the present scenario and the growth prospects of the Global PCOS Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of marketed, off-label, and generic drugs used in the treatment of PCOS. The report, the Global PCOS Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PCOS Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Merck & Co. Inc. - Novartis AG - Sanofi SA - Teva Pharmaceutical Inc. Other Prominent Vendors - AstraZeneca plc - Catalysis SL - Crinetics Pharmaceuticals Inc. - Dexa Medica Group - EffRx Inc. - Neurocrine Biosciences Inc. Market Drivers/Challenges/Trends - Increase in Patient Population. - Lack of Approved Drugs. - Increase in Awareness of PCOS Drugs. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For more information visit http://www.researchandmarkets.com/research/gs...pcos_drugs
NBIX: 18.58 (-0.10), MRK: 59.34 (+0.08), AZN: 72.88 (+0.03), NVS: 91.76 (-0.27)
